Results 11 to 20 of about 43,976 (255)
Transcriptional responses of
BMC Genomics, 2011 Background Burkholderia cenocepacia is a Gram-negative opportunistic pathogen displaying high resistance to antimicrobial peptides and polymyxins. We identified mechanisms of resistance by analyzing transcriptional changes to polymyxin B treatment in ...
Molinaro Antonio +4 more
doaj +2 more sources
Polymyxin B Nephrotoxicity: From Organ to Cell Damage. [PDF]
PLoS ONE, 2016 Polymyxins have a long history of dose-limiting toxicity, but the underlying mechanism of polymyxin B-induced nephrotoxicity is unclear. This study investigated the link between the nephrotoxic effects of polymyxin B on renal metabolic functions and ...
Maria de Fátima Fernandes Vattimo +5 more
doaj +2 more sources
The safety of polymyxin antibiotics [PDF]
Expert Opinion on Drug Safety, 2015 Introduction: The emergence of multidrug-resistant gram-negative bacteria has led to the increasing use of polymyxins. Nephrotoxicity and, to a lesser degree, neurotoxicity occur often during systemic polymyxin therapy. Scientific evidence regarding safety associated with polymyxins remains limited.Areas covered: Case reports/case series, observational
Kelesidis, Theodoros, Falagas, Matthew E
openaire +6 more sources
Synergistic Killing of Polymyxin B in Combination With the Antineoplastic Drug Mitotane Against Polymyxin-Susceptible and -Resistant Acinetobacter baumannii: A Metabolomic Study [PDF]
Frontiers in Pharmacology, 2018 Polymyxins are currently used as the last-resort antibiotics against multidrug-resistant Acinetobacter baumannii. As resistance to polymyxins emerges in A. baumannii with monotherapy, combination therapy is often the only remaining treatment option.
Thien B. Tran +6 more
doaj +2 more sources
Structure-Function Studies of Polymyxin B Lipononapeptides
Molecules, 2019 The emerging threat of infections caused by highly drug-resistant bacteria has prompted a resurgence in the use of the lipodecapeptide antibiotics polymyxin B and colistin as last resort therapies.
Alejandra Gallardo-Godoy +9 more
doaj +2 more sources
Polymyxin B Intravenous Administration Strategy Guided by Minimum Inhibitory Concentration in Critically Ill Patients With Pulmonary Infection: Insights From PBPK Modeling. [PDF]
CPT Pharmacometrics Syst PharmacolPBPK/PD modeling and clinical retrospective validation of intravenous polymyxin B in critically ill patients with pulmonary infection. ABSTRACT Intravenous polymyxin B (PMB) is widely used for treating drug‐resistant gram‐negative pneumonia, though its efficacy in pulmonary infections is considered limited.
Zhang S +9 more
europepmc +2 more sources
mSphere, 2023 Outer membrane vesicles (OMVs) secreted by Gram-negative bacteria serve as transporters for the delivery of cargo such as virulence and antibiotic resistance factors.
Maytham Hussein +9 more
doaj +1 more source
Progress in the study of polymyxin resistance and its mechanism
Shanghai yufang yixue, 2022 Drug-resistant bacteria have become a serious threat to human health. Polymyxin has shown strong bactericidal activity to some Gram-negative and Gram-positive bacteria that are resistant to antibiotics， and has become a last-resort treatment option ...
CAI Jia’an, JIANG Lufang, JIANG Qingwu
doaj +1 more source
, 2020 Resistance to polymyxin antibiotics is increasing. Without new antibiotic classes, combination therapy is often required. We systematically investigated bacterial killing with polymyxin-based combinations against multidrug-resistant (including polymyxin ...
Yu, H +13 more
core +2 more sources